Literature DB >> 6822676

Stability of cyclosporin A in human serum.

J M Smith, J M Hows, E C Gordon-Smith.   

Abstract

Cyclosporin A (CyA), a new immunosuppressive drug, is used for the prevention of organ graft rejection in man. The main side effect of CyA is nephrotoxicity which is usually reversible when the drug is stopped. Nephrotoxicity may be avoided in patients by careful monitoring of serum CyA concentration by radioimmunoassay, in addition to the routine biochemical tests of renal function. There is a good correlation between trough (12 hour) serum concentrations of CyA and plasma creatinine. Cyclosporin A was stable in serum at room temperature for up to seven days and on storage at -20 degrees C for up to five months. Delayed separation of blood stored at room temperature led to increased serum CyA concentrations while blood stored at 4 degrees C before separation was much more stable. Blood samples should be separated as quickly as possible to avoid the release of CyA from the cellular fraction into the serum. Haemolysed samples should be avoided. CyA is sufficiently stable at room temperature for serum samples to be sent in the first class post to a control laboratory for CyA assay, after patients are discharged from the transplant centre. Control and patient serum samples should be stored for a maximum of five months at -20 degrees C prior to assay for CyA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822676      PMCID: PMC498102          DOI: 10.1136/jcp.36.1.41

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  2 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

  2 in total
  5 in total

1.  Recognition of Haemophilus species.

Authors:  K S Zinneman; J D Chapman
Journal:  J Clin Pathol       Date:  1983-06       Impact factor: 3.411

2.  In vitro stability of cyclosporin A.

Authors:  J M Hows; J M Smith
Journal:  J Clin Pathol       Date:  1983-06       Impact factor: 3.411

3.  Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.

Authors:  Lucas Doedens; Florian Opperer; Minying Cai; Johannes G Beck; Matt Dedek; Erin Palmer; Victor J Hruby; Horst Kessler
Journal:  J Am Chem Soc       Date:  2010-06-16       Impact factor: 15.419

4.  Distribution and concentration of cyclosporin in human blood.

Authors:  K Atkinson; K Britton; J Biggs
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

5.  Selective Cyclized α-Melanocyte-Stimulating Hormone Derivative with Multiple N-Methylations for Melanoma Imaging with Positron Emission Tomography.

Authors:  Chengcheng Zhang; Zhengxing Zhang; Jutta Zeisler; Nadine Colpo; Kuo-Shyan Lin; François Bénard
Journal:  ACS Omega       Date:  2020-05-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.